Literature DB >> 9058709

Human platelets display high-affinity receptors for thrombopoietin.

V C Broudy1, N L Lin, D F Sabath, T Papayannopoulou, K Kaushansky.   

Abstract

Thrombopoietin (Tpo) is a major regulator of megakaryopoiesis both in vivo and in vitro. Tpo initiates its biologic effects by binding to the Mpl receptor, which is a member of the hematopoietin receptor family. To define the Tpo binding characteristics of the Mpl receptor, we iodinated purified 70-kD recombinant human Tpo using the Bolton-Hunter reagent. Autoradiographic analysis of (125)I-Tpo binding to normal human marrow mononuclear cells showed many grains specifically associated with megakaryocytes; there were no grains specifically associated with myeloblasts or erythroblasts. Equilibrium binding experiments with (125)I-Tpo and normal human platelets showed a single class of high-affinity receptors (kd, 190 pmol/L) with approximately 30 Mpl receptors per platelet. Affinity cross-linking with (125)I-Tpo showed that the Mpl receptor on platelets is of molecular weight approximately 98 kD. Despite their sequence similarity, erythropoietin and Tpo did not cross-compete for binding to BaF3 cells engineered to coexpress Mpl receptor and erythropoietin receptor. Progeny of normal human burst-forming units-erythroid (BFU-E) contained Mpl receptor mRNA, and flow cytometric analysis showed the presence of Mpl receptor protein on the surface of these cells. These data indicate that display of the Mpl receptor is not limited to the megakaryocytic lineage, but also includes progeny of BFU-E. Like receptors for other hematopoietic cytokines, the binding affinity of the Mpl receptor for Tpo is high, with relatively few receptors displayed per cell. These results suggest that the effects of Tpo to speed red blood cell recovery after myelosuppressive therapy in vivo and to enhance colony-forming unit-erythroid generation in vitro may be mediated by direct interaction of Tpo and erythroid progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058709

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 3.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

4.  Severe thrombocytopenia with iron deficiency anemia.

Authors:  Van K Morris; Holly L Spraker; Scott C Howard; Russell E Ware; Ulrike M Reiss
Journal:  Pediatr Hematol Oncol       Date:  2010-08       Impact factor: 1.969

5.  Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.

Authors:  Silvia Park; Sung Soo Yoon; Jung Hee Lee; Joon Seong Park; Jun Ho Jang; Jong Wook Lee
Journal:  Int J Hematol       Date:  2015-10-28       Impact factor: 2.490

Review 6.  The biology of thrombopoietin and thrombopoietin receptor agonists.

Authors:  David J Kuter
Journal:  Int J Hematol       Date:  2013-07-03       Impact factor: 2.490

7.  Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle.

Authors:  Andreas Rank; Oliver Weigert; Helmut Ostermann
Journal:  Biologics       Date:  2010-05-25

8.  Pharmacokinetic model of target-mediated disposition of thrombopoietin.

Authors:  Feng Jin; Wojciech Krzyzanski
Journal:  AAPS PharmSci       Date:  2004-03-09

Review 9.  New thrombopoietic growth factors.

Authors:  David J Kuter
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

10.  Influence of Intravenous Immunoglobulin Treatment on Thrombopoiesis.

Authors:  Oliver Meyer; Oliver Winter; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2012-05-15       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.